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Abstract
Background:  Somatoform disorders are characterized by the presence of multiple somatic
symptoms without an organic cause that completely explains their symptoms.
These patients generate a high cost in health services. We aim to evaluate the effectiveness and
feasibility of a cognitive-behaviour therapy (CBT) programme, administered in group and individual
formats in primary care for patients who are diagnosed with abridged somatization disorder.
Method/design: Design: Multicentre, randomized, controlled trial involving 3 groups, one of which
is the control group consisting of standardized recommended treatment for somatization disorder
in primary care (Smith's norms) and the 2 others, the intervention groups, consisting of cognitive-
behavioural therapy (10 sessions) administered in individual format (intervention group 1) or in
group format (intervention group 2).
Setting: 29 primary care health centres in the province of Zaragoza and 3 primary care health
centres in the province of Mallorca, Spain.
Sample: N = 204 patients, (68 in each of the three groups), aged 18–65 years, able to understand
and read Spanish, who fulfil Escobar's criteria of Abridgged Somatization Disorder (SSI 4,6), stable
with pharmacotherapy over the previous month, and who will remain stable for the next 3 months
in the doctor's opinion, having signed informed consent.
Intervention: Control group: Standardized recommended treatment for somatization disorder in
primary care (Smith's norms). Intervention group: 10 weekly sessions of CBT, following a protocol
designed by Prof. Escobar's group at UMDNJ, USA. There are 2 different treatment conditions:
individual and group format.
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Measurements: Survey on the use of health services, number and severity of somatic symptoms,
anxiety, depression, quality of life and clinical global impression. The interviewers will not know
which group the patient belongs to (blind). The assessments will be carried out at baseline, post-
treatment, 6 months and 12 post-treatment.
Main variables: Utilization of health services, number and severity of somatic symptoms.
Analysis: The analysis will be per intent to treat. We will use the general linear models of the SPSS
v.15 statistical package, to analyse the effect of treatment on the result variable (utilization of health
services, number and severity of somatic symptoms).
Discussion: It is necessary to develop more effective psychological treatments for somatoform
disorders. This randomised clinical trial will determine whether cognitive behaviour therapy, both
in group or in individual format, is effective for the treatment of these patients.
Trial registration: Current controlled trials ISRCTN69944771
Background
Somatoform disorders, according to the Diagnostic and
Statistical Manual of Mental Disorders [1] are character-
ized by the presence of multiple somatic symptoms with-
out an organic cause that completely explains their
symptoms. This group of disorders include functional
somatic syndromes such as fibromyalgia, chronic fatigue
syndrome or irritable bowel syndrome, diseases increas-
ingly diagnosed at present [2-4]. The most extreme form
of this group is somatization disorder, a chronic and
polysimtomatic disorder, which is characterized by at
least four unexplained symptoms (two gastrointestinal,
one sexual and one pseudoneurological symptoms) [1].
Epidemiological research studies [4,5] demonstrate that
somatoform disorders show a prevalence of 0.1–0.2% in
the general population and 5% in primary care settings.
Although there are no specific studies on the prevalence of
undifferentiated somatoform disorder (less restrictive in
their diagnostic criteria), it is considered the most com-
mon disorder of the group, with a prevalence rate of up to
4.4% in the general population [6] and 22% in primary
care settings [7]. In the United States it is estimated that
health costs of this group of diseases accounts for 10% of
the country's total health care costs [8]. The high percent-
age of work incapacity of these patients, the use of social
services and high psychiatric comorbidity suggest the
need to develop systematic research on these disorders
[9]. In recent years, an abridged form of somatization dis-
order, more prevalent than and with the same severity of
complications and use of health services as somatization
disorder, has been described for research purposes [9].
Somatizing patients mostly attend their primary care phy-
sician [7], so a set of recommendations, called "Smith's
norms" has been developed for the care of these patients
in primary care settings [10,11]. These norms include reg-
ular appointments, systematic exploration of the symp-
toms referred to by the patient, avoidance of unnecessary
diagnostic tests and referrals to appropriate mental health
specialists, among others. At the pharmacological level,
research on specific somatoform disorders are rare, so
there is no a solid foundation on which to build reliable
pharmacological recommendations [12]. However, stud-
ies do exist on the pharmacological treatment of pain (the
main symptom of most somatoform disorders). Accord-
ing to these studies, antidepressant drugs (tricyclic antide-
pressants, mirtazapine, venlafaxine and duloxetine)
[13,14] achieved a significative improvement in these dis-
orders. For the psychological treatment, several interven-
tion programmes (both in individual and group formats)
have been developed. They are based on psychodynamic
psychotherapy [15-17], educational interventions [10,11]
and cognitive-behavioural psychotherapy [18-20]. How-
ever, there are few studies that evaluate the effectiveness of
these interventions [14].
Methods/design
Objectives
The general aim is to evaluate the effectiveness and appli-
cability of a programme of cognitive-behavioural therapy
(individual and group formats) for Abridged somatiza-
tion disorder (SSI 4,6) [9] compared with usual treatment.
The specific aims are:
To determine the effectiveness and cost-effectiveness of
group compared with individual cognitive-behavioural
intervention for patients with Abridged somatization dis-
order.
To identify the variables that predict greater effectiveness
of cognitive-behavioural therapy in somatizing patients.
To determine whether gender differences exist for the var-
iables included in the study.BMC Psychiatry 2008, 8:47 http://www.biomedcentral.com/1471-244X/8/47
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To assess the influence of work incapacity in the evolution
of the symptoms.
Design
This is a multicentre, controlled trial with a random allo-
cation of patients into three alternative branches (see Fig-
ure 1):
1. Standard treatment or "Smith's norms" (control group)
2. Individual cognitive-behavioural therapy (CBT) (inter-
vention group 1)
3. Group CBT (intervention group 2).
The evaluation of the treatment outcomes will be per-
formed at patient level and they will be assessed individu-
ally.
Setting and study sample
Patients will be recruited from any of the 29 primary
health care centres in the province of Zaragoza and 3 in
the province of Mallorca, Spain. Patients will be recruited
by doctors working in these primary care centres until the
required sample is completed, without a quota of patients
assigned for each centre.
Patients considered for inclusion are those aged 18–65
years, able to understand and read Spanish, who fulfil
Escobar's criteria of Abridged Somatization Disorder (SSI
4,6) [9], stable with pharmacotherapy over the previous
month, who will remain stable for the next 3 months in
the doctor's opinion, and who have signed informed con-
sent. Those excluded will be patients with any primary
psychiatric diagnosis other than somatization disorder,
severe personality disorder that prevents an adequate
implementation of the protocol for evaluation and/or
intervention, inability to attend intervention sessions and
refusal to participate.
Figure 1
Randomised allocation of participating 
patients 
Intervention group 1
(Individual CBT) 
Intervention group 2
(Group CBT)  Control group 
Recruited patients  Recruited patients  Recruited patients 
Monitoring: baseline, post-
treatment, 6 months and 12 
months post-treatment 
- Losses 
- Ineligibility 
Included patients  Included patients  Included patients 
- Losses 
- Ineligibility 
Monitoring: baseline, post-
treatment, 6 months and 12 
months post-treatment 
Monitoring: baseline, post-
treatment, 6 months and 12 
months post-treatment 
- Losses 
- Ineligibility 
    Losses      Losses      Losses BMC Psychiatry 2008, 8:47 http://www.biomedcentral.com/1471-244X/8/47
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Randomization, allocation and masking of study groups
Family doctors from the health centres involved in the
study who suspect a patient might fulfil abridged somati-
zation disorder criteria [9] will administer a screening
interview to determine whether the patient meets the
inclusion criteria. Patients who supposedly fulfil these cri-
teria will be interviewed, within the next 10 days, by a
member of the research team for diagnostic confirmation
(baseline). Cases are considered of patients who are diag-
nosed with abridged somatization disorder [9] using the
Standardized polyvalent psychiatric interview or SPPI
[21].
They will be randomly assigned to the three experimental
conditions: individual cognitive-behavioural therapy,
group cognitive-behavioral therapy or usual treatment in
primary care. Each patient will be allocated to one of both
intervention groups or to the control group by means of a
computer-generated random number sequence. The allo-
cation will be carried out by an independent person,
belonging to REDIAPP (Research network on preventative
activities and health promotion), who is not involved in
the study. The method used to implement the random
allocation sequence will be a central telephone. The
sequence will be concealed until interventions are
assigned. Patients agree to participate before the random
allocation and without knowing which treatment they
will be allocated to. CBT treatment will be administered
by two psychologist (SM, NB). Study personnel conduct-
ing psychological intervention (SM, NB) and assessments
(YR, JGC, RM, MR, MG) will be masked to participants'
treatment conditions.
Intervention
Control group or standardized recommended treatment
for somatization disorder in primary care (Smith's norms)
[10,11]: standardized letter to the family doctor with
Smith's norms that includes: 1. Provide brief, regularly
scheduled visits. 2. Establish a strong patient-physician
relationship. 3. Perform a physical examination of the
area of the body where the symptom arises. 4. Search for
signs of disease instead of relying of symptoms. 5. Avoid
diagnostic tests and laboratory or surgical procedures. 6.
Gradually move the patient to being "referral ready".
Experimental or intervention group: establishment of the
protocol developed by Prof. Escobar et al [22] from the
University of New Jersey that includes 10 weekly sessions
of treatment and evaluation over 4 designated times: Time
1 (baseline), Time 2 (aftercare), Time 3 (6 months post-
intervention), and Time 4 (1 year post-intervention).
There will be two different treatment conditions following
the same protocol: individual and group formats. Inclu-
sion in any of the 3 conditions will be random.
Measurements
The study personnel that carried out the measurements
(JGC, RM, YR, MG) will be unaware of which treatment
the patients is being allocated ("blind"). The follow-up
assessments will take place at 4 designated times: time 1
(baseline), time 2 (aftercare), time 3 (6 months post-
intervention), and time 4 (1 year post-intervention).
Variables and instruments of measurements (see Table 1)
Main outcome variables:
- SSS (Severity of somatic symptoms scale) [22]: a scale of
40 somatic symptoms assessed by a 7-point visual ana-
logue scale;
- SSQ (Somatic symptoms questionnaire) [22]: a scale
made up of 40 items on somatic symptoms and patients'
illness behaviour,
Table 1: Study variables
Instrument Assessment area Applied by Times(s) of assessments
Sampling form Age, sex, inclusion/exclusion criteria Family doctor Screening
Othmer and Souza Screening Somatoform disorder Family doctor Screening
Socio-demographic data form Age, sex, marital status, educational level, socio-
economic group, occupation
Research assistant Baseline
EPEP psychiatric interview Psychiatric diagnosis Research psychiatrist Baseline
SOMS Somatic symptoms Research assistant Baseline
SSQ Somatic symptoms Research assistant Baseline
SSS Somatic symptoms Research assistant Baseline and all follow up sessions*
Self-declared health services Use of health services Research assistant Baseline and all follow up sessions*
HAM-D Clinical depression Research assistant Baseline and all follow up sessions*
HAM-a Clinical Anxiety Research assistant Baseline and all follow up sessions*
SF-36 Health and quality of life Research assistant Baseline and all follow up sessions*
CGI Clinical impression Research assistant Baseline and all follow up sessions*
*All follow-up sessions: baseline, post-treatment, 6 months and 12 months post-treatmentBMC Psychiatry 2008, 8:47 http://www.biomedcentral.com/1471-244X/8/47
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- SOMS (Screening for somatoform symptoms) [23,24]: a
53-item screening questionnaire for somatoform disor-
ders with a threshold of 7 symptoms.
- Utilization of healthcare services. Survey of the treat-
ments received (types of drug treatments, individual or
group psychological treatment, use of alternative medi-
cines, etc.).
Secondary variables:
- Socio-demographic variables: age, gender, marital status,
level of education, income, professional qualification,
occupation, current employment status. Survey for the
family doctor on clinical characteristics of the patient (to
be completed by the interviewer based on the medical
record)
- SPPI (Standardized polyvalent psychiatic interview)
[21]: Psychiatric interview designed by our group to diag-
nose psychiatric morbidity in primary care settings [4],
that permits DSM-IV and ICD-10 psychiatric diagnosis. If
the overall score of any of these sections is equal to or
greater than 2, it is considered a positive score in the SPPI
and therefore a "psychiatric case".
- Diagnosis of psychiatric or somatic disease. Causal attri-
bution of the symptoms (psychiatric or physical attribu-
tion) according to the doctor.
- Anxiety and depression levels assessed by Hamilton Test
for Anxiety and Depression (HAM-A and HAM-D)
[25,26].
-Clinical global impression (CGI).
- Quality of life assessed by SF-36 (Survey of health and
quality of life) [27]: Instrument that explores quality of
life related to physical and mental health.
Statistical methods
Sample size
To calculate the sample size we consider that the effective-
ness of usual treatment (Smith's norms) is rather low, esti-
mated at about 20% in most of the variables [10,11]. We
aim to assess whether the new intervention is at least 20%
more effective than usual treatment. Assuming an alpha
risk of 0.05 and a beta risk of <0.20 in a bilateral contrast,
we would need a sample size of 62 patients with abridged
somatization disorder in each group [28]. Furthermore, if
we expect a 10% loss, ie, people who do not complete the
study period, the necessary sample size would be 68
patients in each group, i.e. a total sample of 204 patients.
Analysis strategy
Analysis will be per intent to treat. First we will compare
the two intervention groups (individual and group cogni-
tive-behaviour therapy) and the control group in order to
verify that there are no significant differences among them
(socio-demographic characteristics, clinical baseline data,
etc). We will use the mean (standard deviation) in the
continuous variables and percentages in the categorical
variables. For comparisons we will use the Kruskal-Wallis
test for continuous variables and the Chi-squared test for
categorical variables. Non-parametric tests may also be
used.
The main variables of the result are SSS, SSQ, SOMS and
utilization of healthcare services at 1-year. Process varia-
bles include severity of depression (HAM-D) and anxiety
(HAM-A), clinical global impression (CGI), quality of life
(SF-36), and socio-demographic variables.
We will use the general linear models of the SPSS 15 sta-
tistical package, to analyse the effect of the treatment on
the continuous result variables (SSS, SSQ and SOMS). We
will use the analyses of linear mixed models to analyse the
effect of the continuous process variables (depression,
anxiety, clinical impression, quality of life).
Ethical aspects
Informed consent will be obtained from the participants
before they are aware of which group they are to be
included in. Before they give their consent, the patients
will be provided with a general overview of the aims and
characteristics of the study and the different interventions.
They will also be informed that they will be participating
voluntarily, and that they can choose to withdraw at any
time with the guarantee that they will continue to receive
the treatment considered most appropriate by their doc-
tor. The family doctor of any patients considered "psychi-
atric cases" after administering the psychiatric interview
will be informed recommending appropriate treatment as
usual.
The study follows Helsinki convention norms and poste-
rior modifications and the Declaration of Madrid of the
World Psychiatric Association. The study protocol was
approved by the Ethical review board of the regional
health authority in February 2006 (ref: FIS PI05/2185).
Forecast execution dates
Initial recruitment of patients: June 2008
Finalisation of patient recruitment: December 2008
Finalisation of patient monitoring period: December
2009BMC Psychiatry 2008, 8:47 http://www.biomedcentral.com/1471-244X/8/47
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Publication of results: March 2010
Discussion
The cognitive-behavioural model emphasises the interac-
tion between physiological aspects, cognitions, feelings,
behaviour and environment. From this perspective,
somatoform disorders show distortions at three levels
[28,29]: cognitions (attention focused on the functioning
of the body with a somatic attribution of the symptoms),
behaviour (physical inactivity and continuous seeking of
medical care) and emotions (anxiety and depression).
Furthermore, physiological arousal produces a tendency
to amplify somatosensory information (patients are more
sensitive to bodily sensations). The use of cognitive-
behavioural therapy in somatoform disorders has proven
its effectiveness in several controlled studies, both in
group and individual formats (14–20, 29–31). However,
studies with larger samples and longer follow-up are nec-
essary to confirm that lasting improvements are achieved.
The project presented is a replication of the study carried
out by Prof. Escobar [22] in the USA which has proven
effective in the treatment of somatizing patients in pri-
mary care. The specific features of this project are the fol-
lowing:
- Originality: This is the first intervention study on
somatoform disorders in Spain and one of the first at the
international level that intends to conduct psychological
intervention study in a large sample (N = 204) of primary
care patients with somatoform disorders. In addition, up
to now there have been no studies comparing cognitive-
behavioural therapy administered in groups vs. individ-
ual.
- Clinical impact: It is estimated that more than 20% of
primary care consultations are due to symptoms of
unknown etiology associated with stress and other psy-
chosocial variables.
- Plannification of health resources: Developing effective
treatment protocols allows better planning of human and
technical resources as well as training of health profes-
sionals on the diagnosis and treatment of these disorders
[32].
The main limitations and problems expected are refusals
to participate in the study (due to the negative attitude of
these patients towards psychiatric treatments) or change
in employment status or incapacity to work over the time.
To address the possible bias of disability, which act as a
confounding variable in the analysis of data throughout
the project will evaluate the employment status of
patients who participate in the intervention, asking at
each meeting whether it had changed their status (end of
absence from work, disability... trial). This will attempt to
statistically control the influence of this variable in the
analysis of statistical data.
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